Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer

Authors: Fung Lin Yong, Chee Wei Law, Chee Woon Wang

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs offer great potential as cancer biomarkers. The objective of this study was to correlate the differential expression of miRNAs in tissue and blood in the identification of biomarkers for early detection of colorectal cancer (CRC).

Methods

The study was divided into two phases: (I) Marker discovery by miRNA microarray using paired cancer tissues (n = 30) and blood samples (CRC, n = 42; control, n = 18). (II) Marker validation by stem-loop reverse transcription real time PCR using an independent set of paired cancer tissues (n = 30) and blood samples (CRC, n = 70; control, n = 32). Correlation analysis was determined by Pearson’s test. Logistic regression and receiver operating characteristics curve analyses were applied to obtain diagnostic utility of the miRNAs.

Results

Seven miRNAs (miR-150, miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p) have been found to be differentially expressed in both tissue and blood samples. Significant positive correlations were observed in the tissue and blood levels of miR-193a-3p, miR-23a and miR-338-5p. Moreover, increased expressions of these miRNAs were detected in the more advanced stages. MiR-193a-3p, miR-23a and miR-338-5p were demonstrated as a classifier for CRC detection, yielding a receiver operating characteristic curve area of 0.887 (80.0% sensitivity, 84.4% specificity and 83.3% accuracy).

Conclusion

Dysregulations in circulating blood miRNAs are reflective of those in colorectal tissues. The triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p appears to be a potential blood biomarker for early detection of CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
3.
Bray F, Jemal A, Grey N, Ferlay J, Forman D: Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012, 13 (8): 790-801. 10.1016/S1470-2045(12)70211-5.CrossRefPubMed
4.
American Cancer Society: Cancer Facts & Figures 2012. 2012, Atlanta: American Cancer Society
5.
Zainal Ariffin O, Nor Saleha IT: National Cancer Registry Report 2007. 2011, Malaysia: Ministry of Healthy
6.
McFarland EG, Levin B, Lieberman DA, Pickhardt PJ, Johnson CD, Glick SN, Brooks D, Smith RA: Revised colorectal screening guidelines: joint effort of the American Cancer Society, U.S. Multisociety Task Force on Colorectal Cancer, and American College of Radiology. Radiology. 2008, 248: 717-720. 10.1148/radiol.2483080842.CrossRefPubMed
7.
8.
Neri E, Faggioni L, Cerri F, Turini F, Angeli S, Cini L, Perrone F, Paolicchi F, Bartolozzi C: CT colonography versus double-contrast barium enema for screening of colorectal cancer: comparison of radiation burden. Abdom Imaging. 2010, 35: 596-601. 10.1007/s00261-009-9568-x.CrossRefPubMed
9.
Choong MK, Tsafnat G: Genetic and epigenetic biomarkers of colorectal cancer. Clin Gastroenterol Hepatol. 2012, 10: 9-15. 10.1016/j.cgh.2011.04.020.CrossRefPubMed
10.
Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, de Bruïne AP, Meijer GA, Janssen JB, van Engeland M, Stockbrügger RW, Masclee AA: Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res. 2011, 4 (10): 1563-1571. 10.1158/1940-6207.CAPR-11-0076.CrossRef
11.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average risk population. N Engl J Med. 2004, 351: 2704-2714. 10.1056/NEJMoa033403.CrossRefPubMed
12.
Zou H, Taylor WR, Harrington JJ, Hussain FTN, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, et al: High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009, 136: 459-470. 10.1053/j.gastro.2008.10.023.CrossRefPubMed
13.
U.S. Preventive Services Task Force: Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008, 149 (9): 627-637.CrossRef
14.
Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, et al: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008, 149 (7): 441-450. 10.7326/0003-4819-149-7-200810070-00004.CrossRefPubMedPubMedCentral
15.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.CrossRefPubMed
16.
17.
Li L-C, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R: Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA. 2006, 103 (46): 17337-17342. 10.1073/pnas.0607015103.CrossRefPubMedPubMedCentral
18.
Lee RC, Feinbaum RL, Ambros V: The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993, 75: 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed
19.
Kozamara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39: D152-D157. 10.1093/nar/gkq1027.CrossRef
20.
Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269.CrossRefPubMed
21.
Bueno MJ, Malumbres M: MicroRNA and the cell cycle. Biochim Biophys Acta. 2011, 1812 (5): 592-601. 10.1016/j.bbadis.2011.02.002.CrossRefPubMed
22.
Henegan HM, Miller N, Kerin MJ: MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010, 10: 543-550. 10.1016/j.coph.2010.05.010.CrossRef
23.
Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH: MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011, 47: 163-174. 10.1016/j.ejca.2010.11.005.CrossRefPubMed
24.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004, 101 (9): 2999-3004. 10.1073/pnas.0307323101.CrossRefPubMedPubMedCentral
25.
Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O: Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat Res. 2011, 722: 94-105. 10.1016/j.mrgentox.2010.05.006.CrossRefPubMed
26.
Babashah S, Soleimani M: The oncogenic and tumour suppresive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011, 47: 1127-1137. 10.1016/j.ejca.2011.02.008.CrossRefPubMed
27.
Groce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-714. 10.1038/nrg2634.CrossRef
28.
Liu M, Chen H: The role of microRNAs in colorectal cancer. J Genet Genomics. 2010, 37: 347-358. 10.1016/S1673-8527(09)60053-9.CrossRefPubMed
29.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Lorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103 (7): 2257-2261. 10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral
30.
31.
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem. 2010, 56 (11): 1733-1741. 10.1373/clinchem.2010.147405.CrossRefPubMedPubMedCentral
32.
Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A: Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010, 19 (7): 1766-1774. 10.1158/1055-9965.EPI-10-0027.CrossRefPubMedPubMedCentral
33.
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007, 9: 654-659. 10.1038/ncb1596.CrossRefPubMed
34.
Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Ting Lee M-L, Schmittgen TD, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008, 3 (11): e3694-10.1371/journal.pone.0003694.CrossRefPubMedPubMedCentral
35.
Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F: microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol. 2011, 55: 111-118. 10.1016/j.vph.2011.08.001.CrossRefPubMed
36.
Zhang J, Zhao H, Gao Y, Zhang W: Secretory miRNAs as novel cancer biomarkers. Biochim Biophys Acta. 2012, 1826 (1): 32-43.PubMed
37.
Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010, 107: 810-817. 10.1161/CIRCRESAHA.110.226357.CrossRefPubMed
38.
Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 2012, 7 (1): e29770-10.1371/journal.pone.0029770.CrossRefPubMedPubMedCentral
39.
Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010, 251: 499-505. 10.1097/SLA.0b013e3181cc939f.CrossRefPubMed
40.
Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101 (10): 2087-2092. 10.1111/j.1349-7006.2010.01650.x.CrossRefPubMed
41.
Turchinovich A, Weiz L, Langheinz A, Burwinkel B: Characterization of extracellular miRNA. Nucleic Acids Res. 2011, 39 (16): 7223-7233. 10.1093/nar/gkr254.CrossRefPubMedPubMedCentral
42.
Luo X, Burwinkel B, Tao S, Brenner H: MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev. 2011, 20 (7): 1272-1286. 10.1158/1055-9965.EPI-11-0035.CrossRefPubMed
43.
Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T: The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006, 7: 3-10.1186/1471-2199-7-3.CrossRefPubMedPubMedCentral
44.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4: 249-264. 10.1093/biostatistics/4.2.249.CrossRefPubMed
45.
Jordan JA, Durso MB: Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for Sepsis. J Mol Diagn. 2005, 7 (5): 575-581. 10.1016/S1525-1578(10)60590-9.CrossRefPubMedPubMedCentral
46.
Caraguel CGB, Stryhn H, Gagne N, Dohoo IR, Hammell KL: Selection of a cutoff value for real-time polymerase chain reaction results to fit a diagnostic purpose: analytical and epidemiologic approaches. J Vet Diagn Invest. 2011, 23: 2-15. 10.1177/104063871102300102.CrossRefPubMed
47.
48.
49.
Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, et al: Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 2012, 7 (3): e33663-10.1371/journal.pone.0033663.CrossRefPubMedPubMedCentral
50.
Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH: Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One. 2012, 7 (4): e34150-10.1371/journal.pone.0034150.CrossRefPubMedPubMedCentral
51.
Ahmed FE, Amed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, WIley JE, Allison RR: Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics. 2012, 9 (4): 179-192.PubMed
52.
Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009, 58: 1375-1381. 10.1136/gut.2008.167817.CrossRefPubMed
53.
Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, et al: A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010, 12 (6): 771-779. 10.2353/jmoldx.2010.090169.CrossRefPubMedPubMedCentral
54.
Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M, Beckers J, Siggelkow H, Von Luettichau I, Jundt G, et al: MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012, 205: 212-219. 10.1016/j.cancergen.2012.03.001.CrossRefPubMed
55.
Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68 (7): 2094-2105. 10.1158/0008-5472.CAN-07-5194.CrossRefPubMed
56.
Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gumus ZH, Lipkin SM: miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2012, 2 (6): 540-553. 10.1158/2159-8290.CD-11-0267.CrossRefPubMedPubMedCentral
57.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18: 997-1006. 10.1038/cr.2008.282.CrossRefPubMed
58.
Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M, Li X: MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J. 2010, 277: 3726-3734. 10.1111/j.1742-4658.2010.07773.x.CrossRefPubMed
59.
Chhabra R, Dubey R, Saini N: Cooperative and individualistic functions of the microRNAs in the miR23a ~ 27a ~ 24-2 cluster and its implication in human diseases. Mol Cancer. 2010, 9: 232-10.1186/1476-4598-9-232.CrossRefPubMedPubMedCentral
60.
Willert K, Jones KA: Wnt signaling: is the party in the nucleus?. Genes Dev. 2006, 20: 1394-1404. 10.1101/gad.1424006.CrossRefPubMed
61.
Rogler CE, LeVoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R, Rogler LE: MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting smads. Hepatology. 2009, 50: 575-584. 10.1002/hep.22982.CrossRefPubMed
62.
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller K, De Marzo AM, Van Eyk JE, Mendell JT, et al: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase and glutamine metabolism. Nature. 2009, 458 (7239): 762-765. 10.1038/nature07823.CrossRefPubMedPubMedCentral
63.
Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW, Maurin T, Mari B, Barbry P, Vallar L, Friederich E, et al: Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood. 2009, 113 (2): 412-421.CrossRefPubMed
64.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DLW, Au GKH, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008, 299 (4): 425-436. 10.1001/jama.299.4.425.CrossRefPubMedPubMedCentral
65.
Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008, 47 (3): 897-907. 10.1002/hep.22160.CrossRefPubMed
66.
Wong TS, Liu XB, Wong BYH, Ng WM, Yuen APW, Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008, 14 (9): 2588-2592. 10.1158/1078-0432.CCR-07-0666.CrossRefPubMed
67.
Ju JA, Huang YC, Lan SH, Wang TH, Lin PC, Lee JC, Niu KC, Tian YF, Liu HS: Identification of colorectal cancer recurrence-related microRNAs. GMBHS. 2012, 4: 19-20.
Metadata
Title
Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer
Authors
Fung Lin Yong
Chee Wei Law
Chee Woon Wang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-280

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

Research article

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

Research article

Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas

Technical advance

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing

Research article

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Research article

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits